Aptar, which is a worldwide leader when it comes to drug and consumer product dosing and dispensing, as well as protection technologies, has gone on to announce the strategic acquisition of Sommaplast, which is a specialized provider of oral dosing pharma packaging solutions that is based out of Brazil. This transaction marks a prominent milestone in the expansion strategy of Aptar within the rapidly evolving pharmaceutical sector of Latin America.
The acquisition also brings together two of the industry leaders having complementary strengths within pharmaceutical packaging along with dispensing technologies. The portfolio of Sommaplast includes certain advanced closures, dispensers, and droppers, as well as dosing cups that are especially designed for pharmaceutical as well as nutraceutical applications, hence creating an ideal synergy along with the existing product lines of Aptar.
Expansion strategy of Aptar indeed reinforces its commitment towards expanding its portfolio when it comes to high-growth emerging markets while also at the same time strengthening its position as a complete solutions provider as far as the pharmaceutical packaging industry is concerned. The combination of the global expertise of Aptar with the regional market knowledge from Sommaplast goes on to create a strong platform in terms of accelerated growth.
The pharmaceutical and nutraceutical markets of Brazil are experiencing unmatched growth, which is driven by numerous favorable demographic as well as economic factors. As per Aptar’s president, Gael Touya, Aptar has manufactured in Brazil for 25 years, and this acquisition is anticipated to further reinforce their footprint within the region. It also enables them to position themselves to capitalize on the fast-growing oral dosing, over-the-counter, and nutraceutical markets of Brazil.
It is well to be noted that the Brazilian pharmaceutical market’s expansion is throttled due to three primary elements –  a population base that’s expanding, a rising middle class having increased healthcare spending power, and also an aging demographic that requires more pharmaceutical interventions. These trends go on to create quite significant opportunities for the pharmaceutical packaging providers who are capable of delivering innovative as well as high-quality solutions.
Apparently, the OTC as well as the nutraceutical segments in Brazil are indeed experiencing especially strong growth as consumers growingly go on to give priority to preventive healthcare as well as self-medication alternatives. This transition in consumer behavior demands quite a sophisticated set of packaging solutions that makes sure of precise dosing, protection of the product, and also user convenience.
Founded more than 20 years ago, Sommaplast has gone on to establish itself as a dependable name in the pharmaceutical packaging industry of Brazil. Operating from a state-of-the-art facility that’s located in São Paulo, the company currently employs a dedicated team of more than 400 professionals who get a very deep expertise in the dosing technology along with pharma packaging innovation.
It is worth noting that Sommaplast is indeed recognized throughout the industry for its robust technical team, deep-rooted customer bonds, and also quite exceptional dosing know-how. The reputation of the company in terms of quality as well as reliability has gone on to make it a preferred partner as far as the leading pharmaceutical and nutraceutical manufacturers across Brazil along with Latin America are concerned.
Specializing especially in oral dosing solutions, Sommaplast goes on to manufacture an exhaustive range of pharmaceutical packaging components, which includes the likes of precision closures, metered dispensers, calibrated droppers, and also graduated dosing cups. These products, without a shred of doubt, go on to meet the strict pharmaceutical benchmarks while at the same time addressing the specific requirements when it comes to the Brazilian market.
Due to this acquisition, Aptar would indeed build upon its very impressive 80-year history in terms of innovation as well as excellence within the pharmaceutical packaging landscape. The company has already maintained a steady manufacturing presence in Brazil for a span of years, thereby demonstrating long-term commitment as far as the region is concerned.
At present, Aptar operates manufacturing facilities across four strategic Brazilian locations, namely JundiaÃ, Maringá, Cajamar, and Camaçari. This kind of an extensive network offers quite a comprehensive coverage throughout the key industrial regions of Brazil and also positions the company to go ahead and serve its customers efficiently all across the country.
The Sommaplast acquisition indeed expands the manufacturing footprint and at the same time also brings together complementary production capacities, thereby developing a much stronger as well as more versatile operational platform so as to serve the pharmaceutical industry of Brazil.
Notably, the integration of Sommaplast into the global network of Aptar goes on to promise quite substantial operational synergies and also elevated value delivery to customers throughout both portfolios of the company.
According to Touya, they do plan to further extend the offerings by Sommaplast within the oral dosing pharma markets by way of its strong commercial capacities as well as an expanded product offering. Together, their operational synergies, along with the precision injection molding expertise, are going to greatly benefit the customers. They do intend to maintain the Sommaplast DNA while making utmost use of their global network of solutions and services, as well as product experts.
The amalgamation of the precision injection molding expertise of Aptar along with the dosing technology know-how from Sommaplast goes on to create opportunities in terms of product innovation as well as manufacturing excellence. Customers are going to benefit from the access to a much wider range of solutions that are supported by top-notch technical expertise.
Interestingly, this acquisition goes on to strategically position Aptar to capitalize upon the growth opportunities across the pharmaceutical sector of Latin America. The transaction indeed represents quite a major step in the regional expansion strategy of Aptar, thereby strengthening its capacity to serve the pharmaceutical and nutraceutical manufacturers throughout the continent while at the same time also maintaining the flexibility as well as the customer-centric approach, which has indeed made Sommaplast a successful company.